Altogether, these observations identified this HSP70 inhibitor as a potential therapeutic agent for ABC-DLBCL cases in which Blimp-1 insufficiency is caused by the instability of homogenously expressed, N-terminally misfolded Blimp-1 mutants. Here, PRDM1 is linked to aneurysmal bone cyst.